Cytostatic Activity of Combretastatin A-4 Derivatives in an In Vitro System

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Cytostatic agents are crucial in cancer therapy.
• Combretastatin A-4 and its analogues are investigated for antitumor potential.
• Paclitaxel (Taxacad) serves as a benchmark for drug efficacy.

Purpose of the Study:

• To evaluate the in vitro cytostatic activity of combretastatin A-4 analogues against human cancer cell lines.
• To identify novel, stable, and potent antitumor compounds.
• To compare the efficacy of synthesized compounds with paclitaxel.

Main Methods:

• In vitro evaluation of cytostatic activity.
• Testing on human lung adenocarcinoma (A549) and prostate adenocarcinoma (PC-3) cell lines.
• Determination of half-maximal inhibitory concentration (IC50) values.

Main Results:

• Two isoxazole derivatives, 5-(4-Methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-isoxazole (compound 123124) and 3-(3,4,5-trimethoxyphenyl)-4-(4-methoxyphenyl)-isoxazole (compound 29310186), exhibited the highest cytostatic activity with IC50 values around 8×10⁻⁹ M.
• Two other compounds, (2E)-1-(7-methoxy-2H-1,3-benzodioxol-5-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (compound 104815) and 4-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrazole hydrochloride (compound 198732), showed activity comparable to paclitaxel (IC50 of 65×10⁻⁹ M and 80×10⁻⁹ M, respectively).

Conclusions:

• The identified isoxazole derivatives are highly potent cytostatic agents against lung and prostate cancer cells.
• Compounds 123124 and 29310186 demonstrate significant potential for development into novel antitumor drugs.
• Further investigation into these compounds could lead to new therapeutic strategies for cancer treatment.